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ABSTRACT: The present study screened riboﬂavin mimicking
small molecules to determine their binding activity for the riboﬂavin binding protein. We performed thermodynamic and kinetic
binding studies of these molecules using a combination of two
analytical approaches: isothermal titration calorimetry and surface
plasmon resonance spectroscopy. Screening of a biased set of
nonriboﬂavin-based small molecules by microcalorimetry led to
the discovery of two known drug molecules, quinacrine and
chloroquine, as favorable ligands for the riboﬂavin receptor with
KD values of 264 and 2100 nM, respectively. We further demonstrated that quinacrine is a competitive ligand for the receptor as measured by surface plasmon resonance. Thus, this study describes
the identiﬁcation of a novel class of dual-acting riboﬂavin antagonists that target riboﬂavin receptor for cellular uptake and display
multifunctional activities upon cellular entry.
KEYWORDS: Targeted delivery, riboﬂavin antagonist, isothermal titration calorimetry, surface plasmon resonance spectroscopy
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ater-soluble riboﬂavin (RF, Figure 1) is an essential vitamin
(B2) necessary for the biosynthesis of ﬂavin-based redox
cofactors, such as ﬂavin mononucleotide (FMN) and ﬂavin
adenine dinucleotide (FAD). The cellular availability of this vitamin
for cofactor biosynthesis is mediated by RF receptors that facilitate the uptake of the RF molecules with high eﬃciency.1 The RF
receptors, also referred to as RF carriers, are expressed as both
soluble and membrane-bound isoforms.1 We have recently begun
to explore RF as a ligand for targeting cancer therapy for a number
of reasons. First, RF receptors are identiﬁed to be overexpressed in
certain human cell lines from breast and prostate cancers, potentially making this family of proteins a type of tumor biomarker.2,3
Second, recent studies demonstrated that these membrane-bound
receptors mediate the cellular uptake of natural RF and RF conjugates by receptor-mediated endocytosis.4-6 On the basis of these
studies, we successfully demonstrated receptor-mediated RFtargeted drug delivery to cancer cells in vitro.7 In that study, RFconjugated dendrimer nanoparticles delivered the anticancer drug
methotrexate (MTX) to kill KB cells via receptor-mediated internalization. This work suggested a general route for the selective
delivery of anticancer drug molecules to the cancer cells that overexpress RF receptors.
The present study reports the identiﬁcation and characterization of novel, dual-acting RF antagonists that should make
immediate impacts on RF receptor-mediated cancer targeting.
By deﬁnition, RF antagonists refer to a class of small molecules
r 2011 American Chemical Society

that are structurally related to RF and interfere with the cellular
activity of RF by competitively binding to RF receptors or
enzymes whose activities are associated with ﬂavin cofactors.8,9
We sought to identify dual-acting RF antagonists due to their
potential beneﬁts for targeted delivery in cancer. These RF
antagonists should be able to bind to the RF receptor to mediate
uptake via the internalization of the complex formed with a RF
receptor. However, unlike native RF that has positive trophic
eﬀects on cancer, these molecules can kill cancer cells by interfering with the cellular functions of ﬂavin cofactors such as FMN
and FAD, which are essential for cellular maintenance.9,10 Thus, a
RF antagonist has the potential to function as a dual-acting ligand
in cell targeting.
In an eﬀort to develop RF antagonists for targeted drug delivery
applications, we tried to identify new RF antagonists amenable for
chemical modiﬁcations to allow conjugation to nanoparticles and
have the potential to induce cytotoxicity. To identify such potential
RF antagonists, we searched in the SciFinder Scholar database
focusing on small drug molecules whose core structures mimic the
isoalloxazine head of RF. The rationale for this search is that the
isoalloxazine heterocycle makes a key contribution for the receptor
binding by stacking between the two hydrophobic planes that
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(binding stoichiometry) are shown in Table 1, as are the calculated
estimates for ΔG and ΔS. The nanomolar binding constants obtained for a pH range spanning ﬁve orders of magnitude suggests a
tight binding between RF and RfBP. The binding is optimal at
physiological pH. However, the aﬃnity is signiﬁcantly lower at pH
4, an observation supportive of the mechanism of pH-mediated RF
dissociation in endosomes (pH ∼ 5).6,8 The large ΔH and the
smaller ΔS values indicate that the binding interaction is largely
enthalpy driven. The apparent dissociation constant, KD of 6.6 nM
in 0.1 M phosphate from ITC, is in excellent agreement with two
previous studies involving ﬂuorescence quenching, where a KD of
2 nM was obtained in 0.1 M phosphate buﬀer13 and a KD of 1.3 nM
was obtained in 0.01 M phosphate buﬀer for the RF-RfBP binding
interaction.8
The binding of the ﬁve potential RF antagonists to RfBP was
examined by ITC. A representative binding isotherm is shown for
quinacrine with RfBP in Figure 2c,d, and the thermodynamic
parameters from the binding of the RF antagonists are shown in
Table 2. On the basis of KD, the order of binding strength for RF
and RF antagonists to RfBP is RF > lumiﬂavin > quinacrine >
chloroquine. The order of the binding aﬃnities is determined
primarily by the magnitude of the enthalpic changes (exothermic),
but it is also inﬂuenced by the entropic term especially for those
molecules where the enthalpic contribution is similar (e.g., lumiﬂavin vs quinacrine). Table 2 also shows that ΔH and ΔG values are
closer in magnitude for RF analogues, suggesting that they do not
fully replicate the intermolecular contacts between RF and RfBP.
The diﬀerences in binding entropy are likely due to protein conformational changes upon binding to RF, which do not occur for RF
analogues. Other tested compounds, perphenazine and chlorpromazine, showed no binding aﬃnity toward the RfBP. Although
compounds were selected by structural similarities based on the
tricyclic heterocycle, perphenazine and chlorpromazine are the
only two molecules where a sulfur atom (S) has replaced the N
at the N(5) position in the isoalloxazine ring. The ITC studies
indicate that changes to the N(5) position inhibit the binding of RF
antagonists to RfBP. Because the N(5) position is involved in redox
reactions, it is possible that changes at this position aﬀect binding to
RfBP.1,11 In addition, the ability of N to serve as the H-bond
acceptor may be critical for the tighter binding, while replacement
with S can eliminate such ability. Lumiﬂavin, quinacrine, and
chloroquine show nearly 1-3 orders of magnitude in change in
KD. The major structural diﬀerence among these three RF antagonists is the substituent at position N(10). Clearly, replacement with
a nonribose side chain has an eﬀect of increasing the KD values by
1-2 orders of magnitude in comparison to RF. Furthermore, a
reduction in the binding aﬃnity is achieved by replacing the
alloxazine ring on the heterocycle head of RF. Thus, by screening
several RF-mimicking molecules with polarity and structural similarities to RF, we have demonstrated that binding aﬃnity of RF
antagonists toward RfBP is tunable. While a prior study based on
CD spectroscopy led to an inconclusive result for quinacrine and
chlorpromazine,12 our study shows broad applicability and sensitivity of the ITC method for studies involving RF receptor-ligand
interactions.14 This method enables us to clearly demonstrate the
binding of quinacrine to RfBP at the submicromolar concentration
and to conﬁrm the lack of evidence found for the receptor binding
with chlorpromazine.
On the basis of the ITC studies, we chose quinacrine with a KD
of 0.26 μM for further study by SPR spectroscopy. The present
SPR study for RfBP-ligand interactions is based on an approach
that utilizes the presentation of an RF ligand to the surface of an

Figure 1. Structures of RF, RF-linker (1), and heterocycle-based small
molecules evaluated for their potential activity as the ligands for RF
receptor.

comprise a receptor cleft for mammalian RF binding protein
(RfBP).11 Our structural search led to a small set of compounds
comprised of lumiﬂavin, perphenazine, chlorpromazine, quinacrine, and chloroquine (Figure 1). Of these, quinacrine and chlorpromazine have been previously investigated by circular dichroism
(CD) and ﬂuorescence spectroscopy for the receptor binding, but
no evidence was found for stereospeciﬁc binding of quinacrine and
chlorpromazine, while that study did not rule out the possibility for
complex formation with RfBP.12 Each of the selected molecules
contains a ﬂat heterocycle involving a H-bond acceptor at the
middle of the fused heterocycle, such as pyridine (N) or thiazine
(S) instead of the pyrazine (N) for RF. This study screens these
molecules to determine their binding activity to RfBP using two
well-established methods involving isothermal titration calorimetry
(ITC) and surface plasmon resonance (SPR). The binding experiments are performed with chicken RfBP, a highly validated RF
receptor displaying the signiﬁcant level of interspecies homology in
structure and function,1,8,11 and its results are reported here along
with the thermodynamic and kinetic characteristics of the interaction of each of these small molecules with RfBP.
ITC was ﬁrst used for determining the dissociation constant
and the binding stoichiometry for the interaction between RF
and RfBP at pH 4, 7.4, and 9. Figure 2 shows the ITC thermograms
and the corresponding integrated area of the peaks for RF and
quinacrine binding to RfBP in PBS (0.1 M sodium phosphate,
0.1 M NaCl, pH 7.4). The data in Figure 2b,d were ﬁtted to an
independent model, and the model ﬁt parameters ΔH, KA, and n
364
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Figure 2. Raw ITC data for the interaction between (a) RF (40 μM) and (c) quinacrine (40 μM) with chicken RfBP (4 μM) at 25 C in PBS buﬀer. Plot
of integrated area under each injection peak for RF (b) and quinacrine (d). The solid line (b and d) is an independent model ﬁt to data with parameters n,
KA, and ΔH.

Table 1. Thermodynamic Parameters Showing pH Dependence of the RF System at 25 C
system

a

pH

na

KDa (nM)

ΔHa (kJ mol-1)

ΔG (kJ mol-1)

ΔS (kJ mol-1 K-1)

RF vs RfBP (0.1 M phosphate)

7.4

0.81 ( 0.03

6.6 ( 1.8

-82.2 ( 5.7

-46.6

-0.12

RF vs RfBP (PBS)

7.4

0.78 ( 0.02

5.0 ( 0.7

-91.2 ( 5.7

-47.5

-0.15

RF vs RfBP (0.1 M NaAc)

4.0

0.70 ( 0.04

46 ( 2.8

-100.7 ( 10.4

-41.8

-0.20

RF vs RfBP (0.1 M Tris)

9.0

0.82 ( 0.03

34 ( 3.0

-99.1 ( 9.0

-42.6

-0.19

Reported errors are from ﬁtting data. Error observed between repeats of experiments is similar. KD = 1/KA.

Table 2. Thermodynamic Parameters of RF and RF Antagonists Binding with RfBP in PBS (pH 7.4) at 25 C

a

ΔHa (kJ mol-1)

ΔG (kJ mol-1)

ΔS (kJ mol-1 K-1)

na

KDa (nM)

RF vs RfBP

0.78 ( 0.02

5.0 ( 0.7

-91.2 ( 5.7

-47.5

-0.15

lumiﬂavin vs RfBP

1.08 ( 0.07

61 ( 3.5

-48.2 ( 7.2

-41.2

-0.02

system

quinacrine vs RfBP

0.90 ( 0.04

264 ( 22.1

-51.6 ( 3.9

-37.5

-0.05

chloroquine vs RfBP

1.06 ( 0.04

2100 ( 180

-40.4 ( 2.9

-32.4

-0.03

perphenazine vs RfBP

no binding observed

chlorpromazine vs RfBP

no binding observed

See Table 1.

the protein, a feature reported earlier.15 As a control, bovine
serum albumin did not bind to the RF-presenting surface in a
speciﬁc manner (Figure S3 in the Supporting Information). The
amount of RfBP bound at the surface was analyzed by the
Scatchard plot as a function of the concentrations of RfBP in
the buﬀer (inset in Figure 3). The analysis gave a value for the
equilibrium dissociation constant KD (3.55  10-5 M). The
dissociation constant for RfBP was also calculated by a diﬀerent
method of analysis, where we calculated kinetic binding parameters (oﬀ rate = koﬀ; on rate = kon) by analyzing each sensorgram

SPR sensor chip prepared by immobilization of RF-linker 1
(Scheme S1 in the Supporting Information).15 Binding of RfBP
to the RF-presenting sensor chip was studied by varying the
concentrations of the protein in the range of 33.0 to 3.70 μM
(Figure 3). RfBP bound to the surface in a dose-dependent
manner characterized by the biphasic-like association, noticeably
at higher doses. Such binding features might reﬂect various levels
of accessibility to the hydrated dextran surface presenting RF
ligands or conformational changes of the protein upon ligand
occupation. The binding results also suggest slow dissociation of
365
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Figure 3. Binding of RfBP to the ligand 1 immobilized to a CM5 sensor
chip surface. The concentration of RfBP in the HBS-EP buﬀer (pH 7.4)
is indicated on each of the sensorgrams. The SPR sensorgrams were
corrected for bulk eﬀect (Figure S1 in the Supporting Information;
global ﬁtting curves are shown in dotted lines). The KD was determined
by the Scatchard plot as shown in the inset where RUeq refers to the
response unit (RU) when the protein binding reaches equilibrium on the
surface.

according to BIAevaluation software. Given the
1:1 stoichiometry for the receptor-ligand interaction,8,15 we
utilized the Langmuir model16 for the global curve ﬁtting
(dotted lines in Figure 3) and derived the kinetic parameters
(kon = 1.03  102 M-1 s-1; koﬀ = 1.49  10-3 s-1; χ2 = 2.5). The
resulting equilibrium dissociation constant KD was determined
to be 1.45 ((0.49)  10-5 M. This KD value obtained from the
kinetic analysis is close to the value (KD = 3.55  10-5 M)
determined from the Scatchard analysis for RfBP binding.
The SPR method developed here was then used to screen
RF-mimicking small molecules for inhibiting the adsorption of
RfBP to the chip surface presenting RF ligand 1. As an illustration,
Figure 4 shows that the addition of soluble RF ligand 1 to the RfBPcontaining solution inhibited the binding of RfBP (11.1 μM) to the
surface. The amount of RfBP adsorbed to the surface decreased
with increasing concentrations of 1 in solution in a dose-dependent
manner where approximately 90% of the protein adsorption was
inhibited at the concentrations above ∼500 μM. The results from
the competition experiments suggest that the interaction between
RfBP and 1 immobilized at the surface is biospeciﬁc and can be
competitively blocked by adding free 1 in the solution. The ligand
competition experiment was also performed with RF and quinacrine, the RF-mimicking small molecule identiﬁed as the ligand for
RfBP from the ITC study (Figure 4 and Figure S2 in the Supporting
Information). Each of the experiments suggests for speciﬁc blocking of RfBP adsorption to the surface as a function of the ligand
concentration. On the basis of the SPR results, the inhibition
constant Ki was derived for each ligand according to the solution
competition equation,17 and its values are summarized in Table S2
in the Supporting Information. As a reference molecule, RF has a Ki
value of 0.35 μM, an inhibitory activity approximately 7-fold more
potent than its N(3) derivative 1. In addition, the SPR experiments
demonstrated that quinacrine is a competitive inhibitor for RfBP
with a Ki value of 6.7 μM. Thus, quinacrine has an inhibitory activity
for RfBP ∼19-fold lower than RF.
In summary, the SPR results are in good agreement with the
ﬁndings from the ITC study. It also conﬁrms that quinacrine and
chloroquine are newly identiﬁed members of RF-mimicking

Figure 4. (a) Representative SPR sensorgrams from the competitive
binding experiments with 1. The binding of RfBP (11.1 μM) to the RF
(1)-immobilized chip surface was competitively inhibited by the addition of the soluble ligand 1 to the RfBP solution. The concentrations of
the added RF ligand are indicated in the overlay of the sensorgrams. aAn
example of the control experiment performed by the injection of 1 alone
(220 μM) without RfBP. Each of the RfBP sensorgrams (RfBP þ
ligand) was corrected against the contribution by the soluble ligand
(ligand alone) measured at the designated concentration. (b and c) Plot
of fractional inhibition (F = 1 - RU[I]/RU[I]=0) as a function of inhibitor
(ligand) concentration for each of the competitive inhibitors (RF,
quinacrine, and 1). The response unit (RU[I]) for each sensorgram
was determined by correcting the bulk contribution as described earlier.
The range of inhibition concentrations was lower in the case of
quinacrine due to its limited solubility in the SPR running buﬀer.

competitive ligands. As drugs traditionally used in the treatment
of malaria18 and rheumatoid arthritis,19 these molecules are reported
to display diverse biological activities due to the ability to inhibit a
number of important biological targets such as DNA topoisomerase
II18,20 and metabolic enzymes.21 Recently, quinacrine has generated
new attention because of the discovery that it has antitumoral
activity.22-25 This activity is attributed to its ability to interfere with
cell signaling pathways such as activation of the p53 pathway25 and
inhibition of Bcl-xL, an antiapoptotic protein.23 The present study
suggests another novel application for the quinacrine class of the
drug molecules as ligands that can target RfBP, a vitamin B2 uptake
receptor, in a manner competitive to RF.
366
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Implications for this ﬁnding are many-fold. First, the present
study suggests a new additional perspective for the biological
activities associated with quinacrine and its analogues. On the
basis of the interpretation of our data, it is also conceivable
that quinacrine can interfere with receptor-mediated RF uptake
outside the cell and/or can block a broad range of ﬂavin cofactormediated enzymatic activities after internalization. Second, despite having a moderate aﬃnity to RF receptor at the lower
micromolar concentration, quinacrine can serve as a targeting
ligand for speciﬁc delivery of additional therapeutic molecules
or imaging agents to the receptor-overexpressing cancer cells
implicated in breast and prostate cancers.2,3 Pertinent to this
targeting utility, it would be possible to apply the concept of
multivalent ligand design,7,16,26 in which even suboptimal targeting capability can be enhanced through multivalent tight binding.
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